KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

被引：54

作者：

Cortes, J. ^{[1
,2
,3
,4
]}

Cescon, D. W. ^{[5
]}

Rugo, H. S. ^{[6
]}

Im, S-A. ^{[7
]}

Yusof, M. Md ^{[8
]}

Gallardo, C. ^{[9
]}

Lipatov, O. ^{[10
]}

Barrios, C. H. ^{[11
]}

Perez-Garcia, J. ^{[1
]}

Iwata, H. ^{[12
]}

Masuda, N. ^{[13
]}

Otero, M. Torregroza ^{[14
]}

Gokmen, E. ^{[15
]}

Loi, S. ^{[16
,17
]}

Guo, Z. ^{[18
]}

Zhou, X. ^{[18
]}

Karantza, V. ^{[18
]}

Pan, W. ^{[18
]}

Schmid, P. ^{[19
]}

机构：

[1] Int Breast Canc Ctr IBCC, Quiron Grp, Madrid, Spain

[2] Int Breast Canc Ctr IBCC, Quiron Grp, Barcelona, Spain

[3] Vall dHebron Inst Oncol, Barcelona, Spain

[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain

[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Hematol Oncol, San Francisco, CA 94143 USA

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Pantai Hosp, Ctr Canc, Kuala Lumpur, Malaysia

[9] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile

[10] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia

[11] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Unit, Hosp Sao Lucas, Porto Alegre, RS, Brazil

[12] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan

[13] Natl Hosp Org Osaka Natl Hosp, Breast Oncol, Dept Surg, Osaka, Japan

[14] Oncomedica SA, Hematol & Oncol, Monteria, Colombia

[15] Ege Univ, Fac Med, Sch Med, Izmir, Turkey

[16] Peter MacCallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia

[17] Univ Melbourne, Sir Peter MacCallum Dept Med Oncol, Parkville, Vic, Australia

[18] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA

[19] Ctr Expt Canc Med, Barts Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.2089

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA16

引用

页码：S1289 / S1290

页数：2

共 50 条

[1] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Perez-Garcia, Jose
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhou, Xuan
Karantza, Vassiliki
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2022, 82 (04)
[2] Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Im, Seock-Ah
Cortes, Javier
Cescon, David W.
Yusof, Mastura Md
Iwata, Hiroji
Masuda, Norikazu
Takano, Toshimi
Huang, Chiun-Sheng
Chung, Chi-Feng
Tsugawa, Koichiro
Park, Yeon Hee
Matsumoto, Koji
Inoue, Kenichi
Kwong, Ava
Loi, Sherene
Fu, Wei
Pan, Wilbur
Karantza, Vassiliki
Rugo, Hope S.
Schmid, Peter
NPJ BREAST CANCER, 2024, 10 (01)
[3] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
CANCER RESEARCH, 2017, 77
[4] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
[5] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Colombo, N.
Dubot, C.
Lorusso, D.
Caceres, V.
Hasegawa, K.
Shapira-Frommer, R.
Tewari, K. S.
Salman, P.
Hoyos, E.
Yanez, E.
Gumus, M.
De Mendoza, M. Olivera Hurtado
Samouelian, V.
Castonguay, V.
Arkhipov, A.
Toker, S.
Li, K.
Keefe, S. M.
Monk, B. J.
ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
[7] Additional Efficacy Endpoints From the Phase 3 KEYNOTE-355 Study of Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as First-Line Therapy for Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[8] KEYNOTE-355 Asian subset: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for triple-negative breast cancer
Takano, Toshimi
Cortes, Javier
Cescon, David W.
Im, Seock-Ah
Yusof, Mastura Md
Iwata, Hiroji
Masuda, Norikazu
Huang, Chiun-Sheng
Chung, Chi-Feng
Tsugawa, Koichiro
Park, Yeon Hee
Matsumoto, Koji
Inoue, Kenichi
Kwong, Ava
Loi, Sherene
Fu, Wei
Pan, Wilbur
Karantza, Valia
Rugo, Hope S.
Schmid, Peter
ANNALS OF ONCOLOGY, 2022, 33 : S465 - S465
[9] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes Castan, J.
Guo, Z.
Karantza, V.
Aktan, G.
ANNALS OF ONCOLOGY, 2017, 28
[10] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)

← 1 2 3 4 5 →